Dupixent ® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Regeneron and Sanofi announced that the FDA has approved Dupixent for treating adult patients with bullous pemphigoid (BP), a rare skin disease characterized by intense itch and painful blisters. The approval was based on Phase 2/3 trial data showing that Dupixent led to sustained disease remission in 18.3% of patients versus 6.1% on placebo, and clinically meaningful itch reduction in 38.3% versus 10.5%, along with reduced oral corticosteroid use. This approval marks Dupixent's expansion into its eighth distinct disease indication driven by type 2 inflammation, potentially offering a novel treatment approach for BP patients who have limited therapeutic options.

Analysis

Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi (NASDAQ: SNY) have secured U.S. Food and Drug Administration (FDA) approval for Dupixent® (dupilumab) to treat adult patients with bullous pemphigoid (BP), a chronic and debilitating rare skin disease affecting approximately 27,000 adults in the U.S. with uncontrolled disease. This approval, granted under Priority Review and following an Orphan Drug Designation, marks Dupixent's eighth distinct approved indication for diseases with underlying type 2 inflammation. The FDA's decision was based on pivotal ADEPT Phase 2/3 trial results at 36 weeks, where Dupixent demonstrated notable efficacy: 18.3% of patients achieved sustained disease remission compared to 6.1% on placebo (a 12.2% difference; 95% confidence interval: -0.8% to 26.1%), 38.3% experienced clinically meaningful itch reduction versus 10.5% for placebo, and patients on Dupixent had a lower median cumulative oral corticosteroid (OCS) dose of 2.8 grams compared to 4.1 grams for placebo. This expansion into BP, a condition with limited therapeutic options primarily affecting elderly patients, further solidifies Dupixent's position as a significant multi-indication biologic therapy addressing type 2 inflammation across dermatological, respiratory, and gastrointestinal diseases. Additional regulatory applications for BP are currently under review in the EU, Japan, and China, indicating potential for further global market expansion.

Key Decisions for Investors

• Investors should view this FDA approval as a positive catalyst for Regeneron and Sanofi, expanding Dupixent's addressable market into a rare disease with high unmet medical need, potentially driving incremental revenue growth.
• Consider the consistent expansion of Dupixent's label, now its eighth indication, as a testament to its robust clinical profile and the successful execution of the companies' development strategy, which de-risks future indication expansions.
• Monitor upcoming regulatory decisions for Dupixent in bullous pemphigoid from authorities in the EU, Japan, and China, as approvals in these key markets could further enhance the drug's commercial prospects.
• Evaluate the continued strength of the Regeneron-Sanofi partnership in maximizing Dupixent's lifecycle value, as this approval further solidifies its blockbuster status.